• Stopping immunotherapy in responding melanoma: real-world outcomes

    Lowest risk in patients with complete response, treated over 6 months.

  • AACR 2019—Fecal transplant shows benefit in refractory melanoma

    Clinical and radiological benefit in 2 of 3 patients with anti-PD-1 rechallenge.

  • Melanoma: patient-reported outcomes stable with dabrafenib-trametinib

    COMBI-AD data support adjuvant use for preventing/delaying relapse.

  • Merkel cell carcinoma: study identifies predictors of positive SLN

    Positive sentinel lymph nodes are associated with poorer survival.

  • EU cancer deaths projected to continue declining in 2019

    Reductions in mortality driven by lung cancer in men, breast cancer in women.

  • Nodular melanoma: a distinct clinicopathological profile vs SSM

    Higher mortality risk for nodular subtype, even when ≤1.0 mm.

  • High-risk melanoma: preoperative ctDNA predicts survival in Australian study

    Marker could help stratify patients for adjuvant therapy.

  • Melanoma: tumor thickness tied to recurrence, distant metastasis

    Study sheds light on prognostic factors with surgical excision.

  • Head/neck cSCC: immunosuppression tied to poor survival in Canadian meta-analysis

    Analysis of >3500 patients with regional lymph node metastases.

  • Stage III melanoma: ctDNA predicts high risk for relapse in Australian study

    Assessment can help inform decisions on adjuvant therapy.

  • Head/neck BCC: margins predict postsurgical recurrence

    Locally aggressive BCC of the head and neck is rare and poorly studied.

  • Node-positive MCC: LNR prognostic for postsurgical survival

    LNR can be used to guide management alongside traditional TNM staging

  • Melanoma: less ipilimumab, more nivolumab improves safety

    CheckMate 511 shows similar efficacy, fewer AEs with NIVO3/IPI1 vs NIVO1/IPI3.

  • ASCO-SITC 2019—NKTR-262 + bempegaldesleukin does well in solid-tumor REVEAL

    Data from the ongoing dose-escalation stage of a first-in-human phase 1/2 clinical study.

  • Load more